Up a level |
Rizzato, C, Campa, D, Talar-Wojnarowska, R, Halloran, C ORCID: 0000-0002-5471-4178, Kupcinskas, J, Butturini, G, Mohelníková-Duchoňová, B, Sperti, C, Tjaden, C, Ghaneh, P et al (show 19 more authors)
(2016)
Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients.
Carcinogenesis, 37 (10).
pp. 957-964.
Botla, SK, Savant, S, Jandaghi, P, Bauer, AS, Mucke, O, Moskalev, EA, Neoptolemos, JP, Costello, E, Greenhalf, W, Scarpa, A et al (show 7 more authors)
(2016)
Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression.
Cancer Research, 76 (14).
pp. 4149-4159.
Jandaghi, P, Najafabadi, HS, Bauer, AS, Papadakis, AI, Fassan, M, Hall, A, Monast, A, Doeberitz, MVK, Neoptolemos, JP, Costello, E et al (show 15 more authors)
(2016)
Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
Gastroenterology, 151 (6).
pp. 1218-1231.
Campa, D, Pastore, M, Gentiluomo, M, Talar-Wojnarowska, R, Kupcinskas, J, Malecka-Panas, E, Neoptolemos, JP, Niesen, W, Vodicka, P, Delle Fave, G et al (show 51 more authors)
(2016)
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
ONCOTARGET, 7 (35).
pp. 57011-57020.
Williams, D, Gana, T, Sivapalan, L, Butler, O, Jackson, R, Perez-Mancera, P, Barrera-Briceno, L, Copple, I, Cox, T, Goldring, C et al (show 7 more authors)
(2017)
Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent.
.